IN8bio's Glioblastoma Therapy Extends Survival to Over 19.5 Months, Nearly Doubling Standard of Care
INAB sits 65% above its 52-week low of $1.17.
Summary
IN8bio presented updated clinical data for its DeltEx DRI therapy in newly diagnosed glioblastoma at ASCO 2026, showing median overall survival exceeding 19.5 months, a 48% improvement over standard of care. Median progression-free survival also nearly doubled to 13.0 months. This positive clinical development is critical for the company, which has recently disclosed a going concern warning, a limited cash runway, and initiated a $2.8 million at-the-market offering to secure funding. Strong clinical data in a devastating cancer like glioblastoma is essential for IN8bio's future financing and valuation.
At the time of this announcement, INAB was trading at $1.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.4M. The 52-week trading range was $1.17 to $5.61. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.